New Search

If you are not happy with the results below please do another search

2034 search results for:

431

Algorics acquires Domain Clinical Data Sciences

Algorics, a provider of biostatistics and programming solutions for the pharmaceutical and biotechnology industry, has acquired Domain Clinical Data Sciences (DCDS), a clinical data services organisation based in India.

432

Investors inject €2 million into Abviris to boost HPV cancer biomarker expansion

Abviris Deutschland, a biotech company, has received an injection of €2 million from existing investors to speed up expansion. The move comes after the publication of highly promising results for its pioneering immunoassay biomarker as an aid in the early diagnosis of head, neck and anogenital cancers caused by human papilloma viruses (HPV).

433

Birmingham University, Nonacus partner to develop urine test for bladder cancer

Nonacus, a provider of genetic testing products for precision medicine and liquid biopsy, and the University of Birmingham have partnered to develop a non-invasive urine test for bladder cancer. The test, which is expected to be available by mid-2022, will use highly sensitive liquid biopsy technology developed by Nonacus, and a panel of biomarkers validated […]

434

Thermo Fisher Scientific, Advanced Electrophoresis Solutions agree to combine essential protein separation techniques with mass spectrometry

Thermo Fisher Scientific and Advanced Electrophoresis Solutions (AES), specialists in protein imaging technologies, have agreed to combine essential protein separation techniques with mass spectrometry (MS) to advance therapeutic protein development through streamlined characterization. Together, the companies will promote Thermo Fisher’s expertise as a leading provider of mass spectrometry technology for biopharma and proteomics applications, and AES’ ability […]

435

Selux Diagnostics receives additional $14.6 million in BARDA funding after successfully completing first clinical trial

Selux Diagnostics, which is leading a new era in personalized diagnostics to combat superbug infections and fight antibiotic resistance, has been awarded an additional $14.6 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and […]

436

INTEGRA Biosciences takes significant step towards sustainability

INTEGRA Biosciences has made significant progress towards its goal of minimizing its ecological footprint with the installation of new photovoltaic systems at the company’s US facilities in Hudson, NH. These systems will provide 77 percent of the total energy requirement for both the company’s US headquarters and production centre, saving as much CO2 as 2900 cars […]

439

SignalChem enters clinical trial collaboration with Merck to evaluate effect of SLC-391 in combination with pembrolizumab in advanced NSLC

SignalChem Lifesciences, a clinical-stage company developing novel targeted therapies for oncology, is collaborating with Merck (MSD) through a subsidiary, to evaluate the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced non-small cell lung cancer (NSCLC).

440

Phico Therapeutics awarded up to $18.2 million to advance SASPject antibacterial therapy through Phase 1 clinical trials

Phico Therapeutics, a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to US$18.2 million from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research.